Terry Smith's position in Catalyst Pharmaceuticals is currently worth $53.6M. That's 0.23% of their equity portfolio (33rd largest holding). The investor owns 2.13% of the outstanding Catalyst Pharmaceuticals stock. The investor's estimated purchase price is $61.6M, resulting in a loss of 13%.